Generation Bio Co. is a biotechnology company focused on the development of innovative gene therapies designed to treat genetic diseases. The company leverages its proprietary, immunity-resistant gene therapy platform, which enables the delivery of genetic material to target cells while minimizing immune responses. By working to create durable and targeted therapies, Generation Bio aims to address a range of conditions, including rare genetic disorders, with the goal of improving patients' lives through transformative treatments. Their approach emphasizes precision and efficacy, paving the way for advancements in the field of genetic medicine. Read More
Generation Bio on Tuesday said that it is evaluating strategic alternatives to maximize the value of its assets for shareholders and implementing a strategic restructuring expected to result in a 90% reduction in workforce.
Shares of Sapiens International Corporation NV (NASDAQ:SPNS) rose sharply in pre-market trading after it announced on Wednesday that it will be acquired by global private equity firm Advent in an all-cash transaction
CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, today announced that it will implement a 1-for-10 reverse stock split of the issued shares of the Company’s common stock (“Reverse Stock Split”), effective at 5:00 pm Eastern Time on July 21, 2025. The Reverse Stock Split was approved by the Company’s stockholders at the Company’s Annual Meeting of Stockholders held on June 4, 2025, with the final ratio subsequently determined by the Company’s Board of Directors. One of the primary goals of the Reverse Stock Split is to increase the per-share market price of the Company’s common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market.
CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, today announced that, on July 1, 2025, the company granted equity awards to one new employee, pursuant to the company’s 2025 Inducement Stock Incentive Plan, as an inducement material to such new employee’s entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 4th at 8:10 a.m. ET.
Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.
- Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9th at 12:45 p.m. ET.
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:10 a.m. ET in Boston.
